GET DAILY SIGNALSRelmada Therapeutics (RLMD) Climbs +22.7% in 30 Days on Pipeline Momentum
Key Takeaways
- Relmada Therapeutics (RLMD) rose roughly 22.7% over the last 30 days, climbing from a $3.48 close on October 5, 2026, to a $4.27 close on November 3, 2026.
- The advance marked a rebound from a mid-October low near $3.10, which followed a broader multi-month pullback in the stock.
- The company announced its third-quarter 2026 results date (November 12) and plans to present at the Jefferies Global Healthcare Conference, events that coincided with the latest leg higher.
- Insider purchases by the chief executive officer and chief financial officer, along with a reiterated Buy rating and $19.00 price target from Mizuho Securities, underscored ongoing institutional attention.
- Even with the 30-day gain, RLMD remains down roughly 19% over the trailing three months, reflecting continued repricing of its clinical pipeline.
Company Background and Current Focus
Relmada Therapeutics, Inc. (RLMD) is a clinical-stage biotechnology company based in Coral Gables, Florida, focused on therapies for oncology and central nervous system disorders. Its lead oncology asset, NDV-01, is an intravesical formulation of gemcitabine and docetaxel aimed at non-muscle invasive bladder cancer. The CNS side centers on sepranolone, acquired from Asarina Pharma in early 2025 and under study for Tourette syndrome, Prader-Willi syndrome, and related conditions.
After its prior lead candidate REL-1017 missed key Phase 3 endpoints in depression, the company shifted emphasis to these newer programs, supported by a $160 million private placement completed in March 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Price Action: 30 Days Versus the Quarter
Over the past 30 days, RLMD advanced approximately 22.7%, moving from a $3.48 close on October 5, 2026, to $4.27 on November 3, 2026. The path was uneven, with shares dipping toward $3.10 in mid-October before recovering sharply in the final two weeks.
Looking back three months, the stock is still down roughly 19% from levels near $5.30 in early August. The pattern shows stabilization after the autumn lows, though it remains below summer highs.
Factors Behind the 30-Day Recovery
Management’s open-market purchases of about 200,000 shares by the CEO and CFO in early September provided a positive signal. Mizuho Securities maintained its Buy rating and $19.00 price target, well above current levels. The most recent upward move followed the November 3 announcement of third-quarter 2026 results on November 12 and participation in the Jefferies Global Healthcare Conference, alongside the company’s plan to file INDs for NDV-01 and sepranolone before year-end.
Drivers of the Three-Month Decline
The pullback began after second-quarter results in early August, when a narrower loss per share was overshadowed by concerns over clinical timelines and execution. The September departure of the chief medical officer for urology added uncertainty. The $160 million financing at $4.75 per share also created a lingering dilution overhang, though recent trading suggests investors are now focusing more on upcoming catalysts.
Looking Ahead: Key Events and Risks
The next important date is the November 12 earnings report, where updates on cash and clinical timelines are expected. Progress on IND filings and the Phase 3 RESCUE program for NDV-01 will also matter. Risks include manufacturing execution, regulatory feedback, competition, and typical biotech financing needs. From what I see, the stock’s path will stay closely tied to data and milestones in the small-cap biotech space.
AI Tools in My Research Process
When evaluating names like this, I often review Tickeron’s AI Trend Prediction Engine to cross-check momentum signals against the fundamental story. It provides another layer of perspective on how the broader market is positioning around clinical-stage companies. In my view, combining these quantitative insights with the event calendar helps clarify near-term drivers without overcomplicating the analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RLMD's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for RLMD turned positive on October 20, 2026. Looking at past instances where RLMD's MACD turned positive, the stock continued to rise in 34 of 38 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on RLMD as a result. In 74 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
RLMD moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +19.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where RLMD advanced for three days, in 225 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
RLMD broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RLMD entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.205) is normal, around the industry mean (3.051). P/E Ratio (-4.692) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.120) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. RLMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biotechnology company, which engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases
Industry Biotechnology
Advertisement